<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Treat Options Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Curr Treat Options Allergy</journal-id><journal-title-group><journal-title>Current Treatment Options in Allergy</journal-title></journal-title-group><issn pub-type="epub">2196-3053</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7099688</article-id><article-id pub-id-type="publisher-id">243</article-id><article-id pub-id-type="doi">10.1007/s40521-020-00243-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Allergic Rhinitis (J Maspero, Section Editor)</subject></subj-group></article-categories><title-group><article-title>A Precision Medicine Approach to Rhinitis Evaluation and Management</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Crisci</surname><given-names>Carlos D.</given-names></name><degrees>MD</degrees><address><email>carlosdcrisci@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ardusso</surname><given-names>Ledit R. F.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.10814.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 3211</institution-id><institution>Department of Pulmonology Allergy and Immunology, School of Medicine, </institution><institution>National University of Rosario, </institution></institution-wrap>2000 Rosario, Santa Fe Argentina </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>7</volume><issue>1</issue><fpage>93</fpage><lpage>109</lpage><permissions><copyright-statement>&#x000a9; Springer Nature Switzerland AG 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">Precision medicine (PM) represents a new paradigm in disease diagnosis, prevention, and treatment. The PM approach focuses on the characterization of different phenotypes and pathogenic pathways in order to allow the selection of specific biomarkers that will be useful in disease management. Rhinitis is a highly prevalent and heterogeneous disease, both in terms of underlying endotypes and clinical presentations. Therefore, to apply the PM principles to the various rhinitis subtypes rise as a meaningful strategy to improve evaluation and treatment.</p></sec><sec><title>Recent Findings</title><p id="Par2">The technology of recombinant allergens has allowed molecular characterization of IgE reactivity of specific individual components of allergenic extracts. Recently published and ongoing clinical trials based on component resolved diagnosis (CRD) bring more precision to allergen immunotherapy for allergic rhinitis. Monoclonal antibodies against various cytokines involved in inflammatory allergic and nonallergic rhinitis endotypes show promissory results.</p></sec><sec><title>Summary</title><p id="Par3">Better understanding of pathogenic pathways together with an accurate phenotype classification of patients presented with rhinitis symptoms contributes to point out clinical usefulness of biomarkers and other diagnostic tools, which leads to more accurate environmental control measures, personalized pharmacologic options, and new biological therapy developments.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Precision medicine</kwd><kwd>Rhinitis</kwd><kwd>Phenotypes</kwd><kwd>Endotypes</kwd><kwd>Biomarkers</kwd><kwd>Management algorithm</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Precision medicine (PM) is a growing up new paradigm in disease management [<xref ref-type="bibr" rid="CR1">1</xref>&#x02022;]. PM draws on recent advances in omics sciences, and molecular biology, and bioinformatics, applying them to the evaluation and treatment of health disorders. Based on the knowledge of the pathophysiological mechanisms (endotypes) and the various clinical expressions (phenotypes) of a disease, PM seeks to identify the best management strategies that allow arriving at an accurate diagnosis, which in turns facilitates a predictive, preventive, and therapeutic approach adjusted to the characteristics and needs of the patient, promoting his or her active participation in decision-making [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par5">The three steps of PM are (1) pathophysiology: identification of molecular mechanisms of the disease and its variants, (2) prediction/diagnosis: identification of biomarkers and specific diagnostic tools, and (3) management: blocking/interfere those mechanisms for prevention and/or treatment [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">In multifactorial chronic inflammatory disorders of the upper airway, such as the multiple variants of rhinitis, those endotypes and phenotypes are usually overlapping and dynamic, rendering clear-cut differentiations difficult. To apply a PM approach to this heterogeneous group of diseases acquires potentially greater relevance.</p><p id="Par7">In this article, we will discuss present knowledge and incoming developments for each step in PM approach to rhinitis evaluation and management.</p></sec><sec id="Sec2"><title>Rhinitis subtypes, phenotypes, endotypes, and biomarkers</title><p id="Par8">Chronic rhinitis is one of the most prevalent pathologic conditions of the upper airways, and is usually presented with frequent comorbid conditions, and associated to considerable impact both in quality of life and in financial burden on health care systems [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par9">Rhinitis is characterized by nasal congestion/obstruction, anterior or posterior rhinorrhea, sneezing, and itching [<xref ref-type="bibr" rid="CR5">5</xref>]. However, there is a high variability in both underlying pathophysiologic mechanisms and clinical phenotypes. The three most widely accepted rhinitis subgroups thus far are allergic rhinitis (AR), infectious rhinitis, and nonallergic noninfectious rhinitis (NAR) [<xref ref-type="bibr" rid="CR6">6</xref>], the last one recognizing a wide range of underlying pathophysiologic mechanisms [<xref ref-type="bibr" rid="CR7">7</xref>]. Most relevant pathophysiologic mechanism involved in those types and subtypes of rhinitis (Table <xref rid="Tab1" ref-type="table">1</xref>), as well as potential biomarkers for each endotype, will be briefly discussed.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Classification of rhinitis phenotypes and endotypes</p></caption><graphic position="anchor" xlink:href="40521_2020_243_Tab1_HTML" id="MO2"/></table-wrap></p><sec id="Sec3"><title>Allergic rhinitis</title><p id="Par10">AR is among the most common diseases worldwide and usually persists throughout life [<xref ref-type="bibr" rid="CR8">8</xref>]. The prevalence of AR has been estimated to be approximately 5 to 25% in children [<xref ref-type="bibr" rid="CR9">9</xref>] and more than 40% in adults [<xref ref-type="bibr" rid="CR8">8</xref>]. Common symptoms of allergic rhinitis include sneezing, a runny, stuffy, itchy nose, coughing, a sore or scratchy throat, itchy watery eyes, frequent headaches, and excessive fatigue [<xref ref-type="bibr" rid="CR10">10</xref>]. From a clinical perspective, AR has been classified according to disease severity, and symptom pattern/frequency or seasonality [<xref ref-type="bibr" rid="CR11">11</xref>&#x02022;, <xref ref-type="bibr" rid="CR12">12</xref>&#x02022;].</p><p id="Par11">AR is an inflammatory condition caused by an IgE-mediated response to environmental allergens [<xref ref-type="bibr" rid="CR10">10</xref>]. Nasally inhaled indoor or outdoor allergens, including dust mite, cockroach, animal dander, molds, and pollens, are processed by antigen-presenting cells in the nasal mucosa and presented to T lymphocytes initiating a sensitization response characterized by interleukin (IL)-3, Il-4, IL-5, and IL-13 production [<xref ref-type="bibr" rid="CR13">13</xref>]. These cytokines induce the differentiation of B lymphocytes into plasma cells leading to the production of allergen-specific IgE which in turn binds to high-affinity IgE receptors on the surface of mast cells and basophils [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par12">On aeroallergen re-exposure, the cross-linking of specific IgE molecules by allergenic peptides leads to mast cells or basophil degranulation of preformed (i.e., histamine) and newly formed mediators (i.e., leukotrienes, prostaglandins, platelet-activating factor) [<xref ref-type="bibr" rid="CR15">15</xref>] that are the main responsible of the immediate (within 30&#x000a0;min) allergic symptoms. In many cases, a late-phase reaction took place 4 to 12&#x000a0;h later, due to the release of chemokines and other chemoattractants that induce Th2 cells, activated eosinophils, and mast cell migration into the nasal epithelium where they release additional cytokines, mediators, and enzymes causing delayed allergic symptoms and perpetuating allergic inflammation [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par13">Despite the IgE-mediated inflammatory endotype of AR seems to be sufficiently clear, the resulting phenotypes show multiple expressions. ARIA guidelines [<xref ref-type="bibr" rid="CR11">11</xref>] have categorized AR by duration, either as intermittent (&#x0003c;&#x02009;4&#x000a0;days per week or &#x0003c;&#x02009;4&#x000a0;weeks) or persistent (&#x0003e;&#x02009;4&#x000a0;days per week and &#x0003e;&#x02009;4&#x000a0;weeks) and by severity as mild, characterized by normal sleep, neither impairment of daily activities nor troublesome symptoms, and moderate/severe, associated with impairment of work, leisure, sport, school daily activities, or troublesome symptoms. Although ARIA classification could be certainly useful in terms of AR management by general practitioners, it does not consider the relevance of the allergen or allergens responsible for the sensitization and the triggering of symptoms in each patient, which might be meaningful for a PM approach in terms of diagnostic precision, secondary prevention, and personalized treatment. Following this, molecular characterization of IgE reactivity of specific individual components of allergenic extracts is now possible due to the technology of recombinant allergens. The identification of immunoreactivity to single allergenic components in allergic individuals allows to specifically define patients&#x02019; allergic profile and to obtain the so-termed component resolved diagnosis (CRD) [<xref ref-type="bibr" rid="CR17">17</xref>].</p><sec id="Sec4"><title>Local allergic rhinitis</title><p id="Par14">Local allergic rhinitis, also called entopic rhinitis, is a distinct phenotype characterized by the presence of nasal symptoms of AR in nonatopic patients with negative skin prick test (SPT), undetectable serum-specific IgE against inhalant allergens, but with positive nasal allergen provocation test (NAPT) [<xref ref-type="bibr" rid="CR18">18</xref>&#x02022;&#x02022;]. Local allergic rhinitis (LAR) is a form of chronic rhinitis with localized antigen-specific IgE production to common aeroallergens such as house dust mite and grass pollen [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The mechanism for LAR implies allergen exposure, nasal mucosal production of specific IgE, and a localized Th2 inflammatory response [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par15">Nowadays, in clinical practice, efforts in endotyping patients with rhinitis are mainly limited to measuring total and allergen-specific IgE levels, eosinophilic cationic protein (ECP), and blood and nasal eosinophil counts [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02022;&#x02022;]. Sensitization tests for AR are based on the demonstration of allergen-specific IgE. A positive SPT with allergens provides indirect evidence of allergen-specific IgE on cutaneous mast cells. SPTs are robust and easy-to-use screening instruments for common allergen sources [<xref ref-type="bibr" rid="CR24">24</xref>]. Serologic in vitro diagnostic tests are an alternative option to provide a direct assessment of circulating allergen-specific IgE.</p><p id="Par16">More recently, it has been suggested that the detection of serum IgE to specific molecules such as Phl p 1, Phl p 5, Bet v 1, and Pru p 3 may be also useful as biomarkers to predict seasonal allergic rhinitis persistence and future onset of comorbidities, such as asthma and/or oral allergy syndrome [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par17">In the case of extremely low total serum IgE levels, the basophil activation test (BAT) allows a highly sensitive indirect demonstration of allergen-specific IgE on the surface of human effector cells from fresh blood [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Both BAT and nasal-specific IgE quantification are useful tests for the diagnosis of LAR [<xref ref-type="bibr" rid="CR28">28</xref>]. Nasal allergen provocation test (NAPT) has the capability of differentiating between allergic (AR and LAR) and nonallergic individuals (healthy controls and NAR), as well as between relevant and nonrelevant allergen sensitization in atopic subjects [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par18">Nitric oxide (NO) has been found to be involved in inflammation and to induce regulatory, protective, and defensive tissue-damaging effects. Chemiluminescence represents the gold standard for nasal NO (nNO) measurements as these have a nasal device [<xref ref-type="bibr" rid="CR30">30</xref>]. Increased levels of exhaled nNO have been found in patients with AR compared with normal subjects [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec></sec><sec id="Sec5"><title>Infectious rhinitis</title><p id="Par19">Rhinitis frequently coexists with sinusitis because the nose and sinuses share vascular, neuronal, and anatomic pathways.</p><sec id="Sec6"><title>Acute rhinosinusitis</title><p id="Par20">Acute rhinosinusitis is predominantly of viral origin, with the usual causes being rhinovirus, coronavirus, adenovirus, parainfluenza virus, respiratory syncytial virus, or enterovirus [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Viral rhinosinusitis may be complicated by secondary bacterial superinfection (i.e., <italic>Streptococcus pneumoniae</italic>, <italic>Haemophilus influenzae</italic>, <italic>Moraxella catarrhalis</italic>) that establishes a bacterial rhinosinusitis endotype [<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec7"><title>Chronic rhinosinusitis</title><p id="Par21">Chronic rhinosinusitis is characterized by nasal congestion, purulent discharge, and facial pain which last longer than 12&#x000a0;weeks. The presence or absence of nasal polyps allows further phenotypic classification into chronic rhinosinusitis with or without nasal polyps [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par22">Chronic rhinosinusitis without nasal polyps (CRSsNP) seems to involve Th1 mucosal inflammation and overexpression of transforming growth factor beta resulting in tissue remodeling [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Neutrophils infiltrating nasal biopsy samples as well as nasal fluids IL-6, IL-8, and MPO might be considered as potential biomarkers [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par23">In contrast, the endotype for chronic rhinosinusitis with nasal polyps (CRSwNP) seems to be Th2 driven and characterized by increased levels of IL-4, IL-5, and IL-13 manifested as significant mucosal eosinophilia and increased levels of total and specific IgE [<xref ref-type="bibr" rid="CR37">37</xref>&#x02022;&#x02022;]. Microbial superantigens such as <italic>Staphylococcus aureus</italic> toxins might also play a role throughout basophil degranulation, interaction with the T cell receptor, and specific IgE to <italic>S, aureus</italic> enterotoxin E (SE), the latter one that has been considered as a specific biomarker for CRSwNP [<xref ref-type="bibr" rid="CR38">38</xref>]. On the other hand, reduction in nNO levels was demonstrated in patients with CRSwNP compared with patients with CRSsNP [<xref ref-type="bibr" rid="CR39">39</xref>] (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Potential biomarkers for immune-mediated inflammatory endotypes in rhinitis and chronic rhinosinusitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Endotypes</th><th>Source</th><th>AR</th><th>LAR</th><th>NARES</th><th>CRSwNP</th><th>CRSsNP</th></tr></thead><tbody><tr><td rowspan="4">Type 2 inflammation</td><td>Serum</td><td><p>Eosinophils</p><p>Total IgE</p><p>Specific IgE</p><p>ECP</p></td><td/><td/><td><p>Eosinophils</p><p>Total IgE SE-IgE</p><p>ECP</p></td><td/></tr><tr><td>Nasal fluids</td><td><p>Eosinophils</p><p>IL-5</p><p>IL-4</p><p>IL-13</p></td><td><p>Eosinophils</p><p>Specific IgE</p><p>BAT</p><p>NAPT</p></td><td><p>Eosinophils</p><p>IL-4</p><p>IL.17</p><p>IL-10</p></td><td><p>Total IgE</p><p>IL-5</p><p>IL-14</p><p>ECP</p></td><td/></tr><tr><td>Nasal biopsy</td><td><p>Eosinophils</p><p>ECP</p></td><td/><td>Eosinophils</td><td><p>Eosinophils</p><p>SE-IgE ECP</p></td><td/></tr><tr><td>Nasal exhale</td><td>nNO &#x02191;</td><td/><td/><td>nNO &#x02193;</td><td>nNO &#x02191;</td></tr><tr><td>Non-type 2 inflammation</td><td><p>Nasal fluids</p><p>Nasal biopsy</p></td><td/><td/><td/><td/><td><p>IL-6, IL-8, MPO</p><p>Neutrophils</p></td></tr></tbody></table><table-wrap-foot><p><italic>AR</italic> allergic rhinitis, <italic>LAR</italic> local allergic rhinitis, <italic>CRSsNP</italic> chronic rhinosinusitis without nasal polyps, <italic>CRSwNP</italic> chronic rhinosinusitis with nasal polyps, <italic>NARES</italic> nonallergic rhinitis with eosinophilia syndrome, <italic>SE-IgE</italic> specific IgE to <italic>S. aureus</italic> enterotoxin E, <italic>BAT</italic> basophil activation test, <italic>NAPT</italic> nasal allergen provocation test, <italic>nNO</italic> nasal nitric oxide, <italic>ECP</italic> eosinophilic cationic protein, <italic>MPO</italic> myeloperoxidase</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec8"><title>Noninfectious nonallergic rhinitis</title><p id="Par24">Although it is questionable to define something for what is not, NAR comprises a heterogeneous group of nasal conditions affecting more than 200 million individuals worldwide [<xref ref-type="bibr" rid="CR40">40</xref>]. In this review, we will focus on those subtypes in which PM can provide greater benefits.</p><sec id="Sec9"><title>Nonallergic rhinitis with eosinophilia syndrome</title><p id="Par25">Nonallergic rhinitis with eosinophilia syndrome (NARES) was originally defined by the presence of more than 20% eosinophils in nasal smears without any evidence of IgE-mediated sensitization. Anosmia is a distinctive characteristic not present in AR patients [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. NARES is also a risk factor for the development of nasal polyposis, aspirin sensitivity, bronchial hyperreactivity, and nonallergic asthma [<xref ref-type="bibr" rid="CR43">43</xref>]. The pathophysiology is poorly understood, but a key component involves a self-perpetuating, chronic eosinophilic nasal inflammation which contributes to direct mucosal damage, protracted mucociliary clearance, and nasal hyperresponsiveness. Granules of eosinophils contain toxic basic proteins, the majority of which are eosinophilic cationic protein (ECP), which constitutes a well-standardized marker for tissue eosinophilia and activation [<xref ref-type="bibr" rid="CR44">44</xref>]. ECP levels in nasal secretions can be used to monitor eosinophilic inflammation in different kinds of rhinitis with eosinophilic involvement, and they constitute an indicator of the efficacy of treatment [<xref ref-type="bibr" rid="CR44">44</xref>]. NARES is not associated with local allergy (entopy) nor with a local inflammation driven by <italic>Staphylococcus aureus</italic> enterotoxin [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec10"><title>Idiopathic rhinitis/vasomotor rhinitis</title><p id="Par26">Idiopathic rhinitis (IR) is the most prevalent subtype of the NAR group, and is also a diagnosis requiring exclusion of AR, nasal eosinophilia, structural defects, or underlying systemic disease [<xref ref-type="bibr" rid="CR46">46</xref>]. In the absence of any cellular inflammatory pattern, the pathophysiologic mechanism in IR is likely to be neurogenically mediated [<xref ref-type="bibr" rid="CR37">37</xref>]. Most common triggers of symptoms include chemical irritants, as tobacco smoke, perfumes, and cleaning agents, but also changes in temperature, humidity, and barometric pressure, as well as alcohol ingestion. A neural/vascular pathophysiologic mechanism has been initially proposed to explain the effect of nonspecific irritants and alcohol, by inducing tachykinin release and inhibition of sympathetic mediators, enhancing the parasympathetic response therefore ending in nasal congestion and/or rhinorrhea [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par27">Another group of evidences suggests that IR may be disorders of the nonadrenergic noncholinergic or peptidergic neural system [<xref ref-type="bibr" rid="CR48">48</xref>]. Nasal peptidergic neurons (mainly sensory C fibers) activated by these nonspecific stimuli resulted in antidromic and orthodromic release of inflammatory neuropeptides, which can exert effects on the blood vasculature and mucus-secreting glands, leading to symptoms of IR.</p><p id="Par28">The neurogenic rhinitis endotype could also help to explain gustatory rhinitis and rhinitis of the elderly as well as some features of acute viral rhinitis (cold air responsiveness) and even AR (which have neural inflammation that leads to nonspecific hyperreactivity [<xref ref-type="bibr" rid="CR49">49</xref>]. <italic>Rhinitis of the elderly</italic>, commonly presents with profuse rhinorrhea, is attributed to nasal hyperresponsiveness of the parasympathetic system [<xref ref-type="bibr" rid="CR50">50</xref>]. <italic>Gustatory rhinitis</italic> defined by the acute onset of profuse watery rhinorrhea immediately after ingestion of certain spicy foods or after any act of eating is also associated with overstimulation of the parasympathetic system [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par29">Several biomarkers might be used, mainly in research settings, such as substance P and neurokinin 1 [<xref ref-type="bibr" rid="CR52">52</xref>&#x02022;&#x02022;]. Staining of mucosal biopsy specimens for transient receptor potential cation channel subfamily V member 1 (TrpV1), also known as the capsaicin receptor, zonula occludens 1, or occluding has been used for similar purposes [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec11"><title>Hormonal rhinitis</title><p id="Par30">Hormonal rhinitis subtypes include rhinitis of pregnancy and menstrual cycle&#x02013;related rhinitis. Rhinitis of pregnancy typically begins after 34&#x000a0;weeks of gestation and resolves spontaneously within 2&#x000a0;weeks postpartum [<xref ref-type="bibr" rid="CR54">54</xref>], whereas menstrual cycle&#x02013;related rhinitis consists of symptoms appearing in the last few days of the menstrual cycle. The subjacent endotype might be primarily mediated either through increased levels of estrogen, which cause nasal congestion through vascular engorgement or by a vasodilating effect of progesterone [<xref ref-type="bibr" rid="CR55">55</xref>]. Other mechanisms have also been suggested, including increased production of human growth hormone, enhanced production of a placental growth hormone variant, or of prolactin.</p></sec><sec id="Sec12"><title>Drug-induced rhinitis</title><p id="Par31">From a pathophysiologic perspective, systemic drug-induced rhinitis may be classified into three subtypes: local inflammatory, neurogenic, and idiopathic types.</p><p id="Par32">The prototype of the inflammatory endotype is represented by aspirin-exacerbated respiratory disease (AERD). This condition is characterized by hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs leading to upper and lower airway inflammation, and resulting in severe rhinosinusitis and asthma symptoms [<xref ref-type="bibr" rid="CR56">56</xref>]. Inhibition of cyclooxygenase-1 shifts the metabolism of arachidonic acid to the lipooxygenase pathway, resulting in increased cysteinyl leukotriene release precipitating local inflammation. The diagnosis of NAR is based on a detailed medical history and exclusion of clinically relevant sensitization to airborne allergens, and exclusion of clinical signs of rhinosinusitis. In the absence of atopy and negative SPT, increased nasal eosinophil counts and higher baseline levels of urinary LTE<sub>4</sub> would be considered a specific biomarker for AERD [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par33">Alpha-adrenergic and beta-adrenergic antagonists (clonidine, methyldopa) could mediate symptoms of rhinitis throughout a neurogenic endotype. Downregulation of the sympathetic tone leads to vascular engorgement, nasal congestion, and rhinorrhea. Phosphodiesterase-5 selective inhibitors such as sildenafil, tadalafil, and vardenafil, which act through their vasodilating properties on the erectile tissue of the nasal turbinates, are other examples of this neurogenic endotype. ACE inhibitors resulting in increased release of bradykinin, which is a potent vasodilator, might be also included in this subtype [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par34">Other drugs (e.g., beta-blockers, calcium channel blockers, antipsychotics) [<xref ref-type="bibr" rid="CR46">46</xref>] could induce rhinitis by still unknown pathophysiologic mechanisms (idiopathic endotype).</p></sec><sec id="Sec13"><title>Rhinitis medicamentosa</title><p id="Par35">Rhinitis medicamentosa is defined as rebound nasal congestion following excessive local use of decongestant sprays. Nasal vasoconstrictors like sympathomimetics and imidazolines, but also coacaine, are the main responsible drugs [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par36">As the diagnosis lies on clinical history and physical examination (swollen, red nasal mucous membranes with minimal discharge), and management seems obvious, then pathophysiological mechanism merits not further discussion.</p></sec><sec id="Sec14"><title>Occupational rhinitis</title><p id="Par37">Work-related rhinitis includes the development of nasal symptoms caused by factors in the work environment as well as work-exacerbated rhinitis, in which a preexisting or concurrent rhinitis is worsened by occupational factors. The nature of the workplace airborne agent exposure and the pathophysiological mechanisms involved may distinguish between allergic and nonallergic endotypes [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par38">High-molecular-weight agents such as animal (rodents) proteins and some low-molecular-weight agents (platinum salts) are complete antigens capable to elicit a specific IgE-mediated response by itself. Others low-molecular-weight agents (diisocyanates, trimellitic acid) act as haptens, which need to bind endogenous proteins in order to initiate a specific IgE-mediated response.</p><p id="Par39">On the other hand, a single exposure to high chemical irritant concentrations or multiple exposures to lower chemical irritant concentrations over time (chlorine, sulfur dioxide, and ammonia) [<xref ref-type="bibr" rid="CR60">60</xref>] can lead to significant inflammation and even structural damage. Such irritant-mediated nonallergic endotype has been termed as reactive upper airway dysfunction syndrome, irritant-induced rhinitis, or corrosive rhinitis depending on the severity and long lasting of the process [<xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par40">The scarcity of specific biomarkers for NAR reinforces the need to implement other complementary evaluation tools, such as nasal flow measurement (to confirm nasal obstruction), cold dry air provocation (to search for nasal hyperreactivity), nNO measurement (to evaluate nasal inflammation), and test for smell performance (in NARES and other patients mentioning reduced smell capacity). Nasofibroscopy and axial computed tomography will help to evaluate anatomical alterations or the presence of chronic rhinosinusitis with or without polyps, or any evidence of atrophic rhinitis [<xref ref-type="bibr" rid="CR62">62</xref>].</p></sec></sec></sec><sec id="Sec15"><title>Treatment of rhinitis subtypes following PM principles</title><p id="Par41">Patients with moderate-to-severe rhinitis who are inadequately controlled despite treatment according to current rhinitis management guidelines have a negative impact on daily functioning and are at risk of developing serious comorbidities, such as asthma and chronic rhinosinusitis. PM strategies, based on endotype-driven management, represent the future of rhinitis care in patients whose symptoms are not fully controlled despite evidence-based treatment.</p><p id="Par42">Current definition of rhinitis relies on the combination of history, physical examination, and allergy diagnostic testing, which allows the distinction of the previously stated three major subgroups: allergic, infectious, and nonallergic noninfectious rhinitis.</p><p id="Par43">The first step in the implementation of PM in patients with rhinitis, that is to characterize the endotype, will be a guide to a tailored management approach. Furthermore, we have to keep in mind that there are several modulators of endotype expression, such as the environment, microbiome, lifestyle, and nasal anatomy.</p><p id="Par44">The best example of an endotype-driven treatment in AR is the use of allergen-specific immunotherapy in patients in whom an allergen-induced type 2 immune response endotype leads to a clinically relevant exposure-symptom relation. Other examples aiming to interfere with type 2 immune response include biological treatments with monoclonal antibodies targeting either IL-5 or IL4 receptor in CRSwNP. On the other hand, NAR phenotypes warrant different treatment strategies depending on the known or suspected underlying etiology, being it inflammation, neurogenic dysfunction, environmental exposure, and/or medication use.</p><sec id="Sec16"><title>Allergen immunotherapy</title><p id="Par45">Allergen immunotherapy (AIT) represents an important intervention, currently adjunctive to pharmacological treatment, which confers specific advantages over conventional management.</p><p id="Par46">The decision to prescribe AIT for the patient should be individualized and based on the clinical relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Until now, there are no currently available validated biomarkers that can predict AIT success [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par47">The first premise for the prescription of immunotherapy based on CRD is the assessment of IgE positivity to genuine versus cross-reactive allergens. Precise identification of relevant sensitizers in the case of pollen-allergic patient&#x02019;s monosensitized or oligosensitized to pollens with no overlapping pollen season can be achieved by conventional diagnosis with complete pollen extracts. In most cases, patients are sensitized to major pollen allergens, but this may not be the case in areas with high pollen loads. When prescribing AIT in areas with high frequency of sensitization to &#x0201c;minor allergens,&#x0201d; molecular diagnosis may be of special interest, since commercial extracts for immunotherapy are well standardized only for major allergens [<xref ref-type="bibr" rid="CR64">64</xref>]. Thus, patients with sensitization to minor allergens alone may likely not receive sufficient amounts of antigen to achieve a successful outcome from AIT, or even worse will experience adverse reactions when the concentrations of this minor allergens present in the extract are high [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par48">In addition, AIT would be appropriately prescribed if sensitization to the species-specific allergens is confirmed in pollen allergies, while in the case of selective recognition of cross-reactive allergens, like profilins and polcalcin, called &#x0201c;pan-allergens&#x0201d; because the highly conserved structure and ubiquitous distribution of these molecules among plant species or cross-reactive carbohydrate determinants presents in the glycoproteins of virtually all pollen, the indication of AIT is arguable. Cross-reactive allergens seem to have limited clinical relevance and besides their content in AIT extracts is usually not quantified [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec17"><title>Biological agents</title><p id="Par49">Although biological agents have been studied for the treatment of patients with AR, none of them is currently approved for the treatment of AR alone.</p><p id="Par50">Omalizumab is a humanized anti-IgE monoclonal antibody that binds free IgE, preventing binding to receptors on mast cells and basophils. This agent can also decrease IgE receptors on effector cells. A meta-analysis of randomized clinical trials (RCTs) to assess the efficacy and safety of omalizumab in poorly controlled allergic rhinitis, which included 11 studies and 2870 patients, concluded that omalizumab is significantly associated with symptom relief, decreased rescue medication use, and improvement of quality of life [<xref ref-type="bibr" rid="CR67">67</xref>&#x02022;].</p><p id="Par51">It is probably that due to its high cost, omalizumab should not be used as monotherapy in the treatment of AR but may be considered in combination with AIT for highly sensitive poly-allergic rhinitis patients with increased risk of anaphylaxis [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par52">Monoclonal antibodies have been proposed as a novel therapy in patients suffering from CRSwNP. In two recent meta-analyses [<xref ref-type="bibr" rid="CR69">69</xref>&#x02022;, <xref ref-type="bibr" rid="CR70">70</xref>], anti-IgE therapy with omalizumab was assessed in two studies, anti-interleukin IL-5 therapy in three studies (one reslizumab, two mepolizumab), and anti-IL-4 and anti-IL-13 (dupilumbab) therapy in three studies. Biologic therapy was proved to be effective in reducing total nasal endoscopic polyp score and improving several other outcomes, such as opacification in computed tomography, quality of life measures, nasal airflow, and olfaction and type 2 associated biomarkers. Very recently, add-on dupilumab to inhaled corticosteroids resulted in significant and clinically meaningful improvements in endoscopic, radiologic, clinical, patient-reported sino-nasal, and asthma outcomes in patients with CRSwNP [<xref ref-type="bibr" rid="CR71">71</xref>]. Other biological agents targeting Siglec-8 and IL-33 appear promissory [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par53">Macrolide antibiotics have demonstrated great benefit in CRSsNP when used for their antiinflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as IL-8 and tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) [<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec18"><title>Environmental control</title><p id="Par54">The prevalence of AR as well as other allergic diseases has been increasing for at least five decades. A possible cause of this increase could be the exposure of genetically predisposed individuals to a constantly changing indoor and outdoor environment. Two of these changes strongly implicated in the sensitization process and in the triggering of symptoms of allergic diseases are air pollution and global warming induced by climate change, factors which are closely related to each other [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par55">Experimental and epidemiological studies have shown a positive correlation between climate change, air pollution, and the incidence of respiratory allergic diseases [<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>]. Therefore, it is expected that any intervention that can be done to improve the environment would benefit the general population at large, and patients with AR. It could reduce the possibility of developing allergic diseases, facilitate treatment, and improve the quality of life of these patients [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par56">Home environmental interventions (acaricides and bedroom control programs) may be of some benefit in reducing dust mite load and rhinitis symptoms [<xref ref-type="bibr" rid="CR78">78</xref>]. One of the main problems to achieve an effective eradication of allergens lies in the adherence or compliance with the recommendations of these measures, since it may require modifications of the house, control of moisture sources, control of pets and insects, and improvements in the ventilation of the house, among others [<xref ref-type="bibr" rid="CR79">79</xref>].</p><p id="Par57">Regarding the general external environment, it is clear that it depends mainly on state policies tending to modify behaviors and actions both of the individual (recycling of organic material, use of biodegradable products, etc.) and of the general population (emission control of gases, promote the development of nonpolluting energies, active control of both the construction of &#x0201c;healthy&#x0201d; homes, the use of pesticides, the emission of gases by industrial activity, etc.). These holistic changes in lifestyle will have an impact on the global health of the human being and not only on patients with AR.</p></sec><sec id="Sec19"><title>PM treatment approach for NAR</title><p id="Par58">Avoidance of the etiological agent is the preferred management option in many patients with neurogenic inflammation-driven endotype (occupational rhinitis, gustatory rhinitis) and neuronal imbalance (rhinitis medicamentosa). Irritant avoidance and smoking stop should be advised to all rhinitis patients [<xref ref-type="bibr" rid="CR80">80</xref>&#x02022;]. In the same way, treatment of the drug-induced phenotypes of NAR primarily will consist of avoidance of the drug, but aspirin-intolerant individuals may benefit from aspirin desensitization [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par59">The inflammatory group (occupational rhinitis and drug-induced rhinitis) may benefit from antiinflammatory treatment such as nasal corticosteroids and nasal antihistamines.</p><p id="Par60">The treatment of noninflammatory phenotypes of NAR is diverse depending on the presumed pathophysiology. Ipratropium bromide is an anticholinergic drug and the first treatment option in rhinitis in the elderly [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par61">Another example of endotype-driven treatment is the highly successful intervention with capsaicin for the neurogenic noninflammatory endotype. Capsaicin treatment in patients with IR produced symptomatic relief and reduced the expression of transient receptor potential cation channel subfamily V, receptor 1 (TRPV1). Capsaicin did not alter nasal epithelial morphology nor did it induce apoptosis or necrosis in cultured human nasal epithelial cells and mast cells [<xref ref-type="bibr" rid="CR53">53</xref>]. Since many years, the use of azelastine has been found to be effective in NAR patients, but only recently, azelastine has been demonstrated to exhibit TRPV1 channel activity through the modulation of Ca2+ signaling on sensory neurons and in nasal epithelial cells [<xref ref-type="bibr" rid="CR83">83</xref>].</p></sec></sec><sec id="Sec20"><title>Conclusions</title><p id="Par62">Precision medicine implies the incorporation of a wide array of individual data, including clinical, lifestyle, genetic, and further biomarker information.</p><p id="Par63">PM focuses on the stratification of patients beyond the classical &#x0201c;signs-and-symptoms&#x0201d; approach, identifying modifiable traits that can be treated in a better way because of more precise and validated phenotypic recognition or due to a better understanding of the critical causal pathways.</p><p id="Par64">Although often underestimated, rhinitis is one of the most common chronic diseases worldwide, with increasing prevalence, morbidity, and greater impact in quality of life. Very recently, a new initiative has been launched in the field of PM with the aim of promoting the circulation of knowledge in the field of personalized, predictive, preventive, and participatory medicine in the field of allergic diseases and respiratory medicine (IMPERA) [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par65">The three most widely accepted rhinitis subgroups thus far are infectious rhinitis, AR, and NAR. Underlying mechanisms are as numerous and diverse as the disease&#x02019;s phenotypes and are largely overlapping, making a clear demarcation challenging.</p><p id="Par66">A PM approach to rhinitis evaluation and management is schematically summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The first step is based on medical history and physical examination, and search for environmental exposure and lifestyle. The second step includes basic laboratory tests and nasal structural and functional evaluation. To further characterization, in deep evaluation requires identification of specific biomarkers, mainly available in research settings. The third step consists on the implementation of specific preventive measures and endotype-driven therapeutic options. The greatest advances have been made in the field of AIT and in the inhibition or blockade of some of the molecules associated with the immune mediated endotype. However, more studies are still mandatory for those phenotypes associated to neurogenic and idiopathic endotypes.<fig id="Fig1"><label>Fig. 1</label><caption><p>A precision medicine approach to rhinitis evaluation and management. NHR nasal hyperreactivity, nNO nasal nitric oxide, ACT axial computed tomography, SPT skin prick test, ECP eosinophylic cationic protein, HMW high molecular weight, AR allergic rhinitis, ARIA allergic rhinitis and its impact on asthma guide, NAPT nasal allergen provocation test, AIT allergen immunotherapy, NAR nonallergic rhinitis, NARES nonallergic rhinitis with eosinophilia syndrome, CRSwNP chronic rhinosinusitis with nasal polyps, CRSsNP chronic rhinosinusitis without nasal polyps, sIgE-SE specific IgE against to <italic>S. aureus</italic> enterotoxin E, MPO myeloperoxidase, SP substance P, TRPV-1 transient receptor potential cation channel subfamily V member 1, LTE4 leukotriene E4, AERD aspirin-exacerbated respiratory disease, Mab monoclonal antibody. Asterisk indicates Mab target cytokines IL-4/IL-13 (dupilumab) via blocking the IL-4 receptor alpha, IL-5 (mepolizumab), and IL-5 receptor alpha (benralizumab) as well as IgE (omalizumab)<italic>.</italic></p></caption><graphic xlink:href="40521_2020_243_Fig1_HTML" id="MO1"/></fig></p></sec></body><back><fn-group><fn><p>This article is part of the Topical Collection on <italic>Allergic Rhinitis</italic></p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Compliance with Ethical Standards</title><notes notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par67">Carlos Crisci declares that he has no conflict of interest. Ledit Ardusso declares that he has no conflict of interest.</p></notes><notes><title>Human and Animal Rights and Informed Consent</title><p id="Par68">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References and Recommended Reading</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#x02022; Of importance &#x02022;&#x02022; Of major importance</title><ref id="CR1"><label>1&#x02022;</label><mixed-citation publication-type="other">K&#x000f6;nig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? European Respiratory Journal. 2017;50(4). 10.1183/13993003.00391-2017This is a good article to understand what precision medicine is about.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagner</surname><given-names>M</given-names></name><name><surname>McNeil</surname><given-names>A</given-names></name><name><surname>Puska</surname><given-names>P</given-names></name><name><surname>Auffray</surname><given-names>C</given-names></name><name><surname>Price</surname><given-names>ND</given-names></name><etal/></person-group><article-title>The P4 health spectrum&#x02014;a predictive, preventive, personalized and participatory continuum for promoting healthspan</article-title><source>Prog Cardiovasc Dis</source><year>2017</year><volume>59</volume><issue>5</issue><fpage>506</fpage><lpage>50\</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2016.08.002</pub-id><?supplied-pmid 27546358?><pub-id pub-id-type="pmid">27546358</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamburg</surname><given-names>MA</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name></person-group><article-title>The path to personalized medicine</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>4</issue><fpage>301</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1006304</pub-id><?supplied-pmid 20551152?><pub-id pub-id-type="pmid">20551152</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keswani</surname><given-names>Anjeni</given-names></name><name><surname>Peters</surname><given-names>Anju T.</given-names></name></person-group><article-title>Complications of Rhinitis</article-title><source>Immunology and Allergy Clinics of North America</source><year>2016</year><volume>36</volume><issue>2</issue><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2015.12.011</pub-id><pub-id pub-id-type="pmid">27083108</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WALLACE</surname><given-names>D</given-names></name><name><surname>DYKEWICZ</surname><given-names>M</given-names></name><name><surname>BERNSTEIN</surname><given-names>D</given-names></name><name><surname>BLESSINGMOORE</surname><given-names>J</given-names></name><name><surname>COX</surname><given-names>L</given-names></name><name><surname>KHAN</surname><given-names>D</given-names></name><name><surname>LANG</surname><given-names>D</given-names></name><name><surname>NICKLAS</surname><given-names>R</given-names></name><name><surname>OPPENHEIMER</surname><given-names>J</given-names></name><name><surname>PORTNOY</surname><given-names>J</given-names></name></person-group><article-title>The diagnosis and management of rhinitis: An updated practice parameter</article-title><source>Journal of Allergy and Clinical Immunology</source><year>2008</year><volume>122</volume><issue>2</issue><fpage>S1</fpage><lpage>S84</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2008.06.003</pub-id><pub-id pub-id-type="pmid">18662584</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastin</surname><given-names>T</given-names></name></person-group><article-title>Recognizing and treating non-infectious rhinitis</article-title><source>J Am Acad Nurse Pract</source><year>2003</year><volume>15</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7599.2003.tb00414.x</pub-id><?supplied-pmid 14560436?><pub-id pub-id-type="pmid">14560436</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaliner</surname><given-names>M</given-names></name></person-group><article-title>Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic rhinopathy</article-title><source>World Allergy Organ J</source><year>2009</year><volume>2</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1097/WOX.0b013e3181a9d55b</pub-id><?supplied-pmid 24229372?><pub-id pub-id-type="pmid">24229372</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bro&#x0017c;ek</surname><given-names>JL</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Baena-Cagnani</surname><given-names>CE</given-names></name><name><surname>Bonini</surname><given-names>S</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Casale</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><fpage>466</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.047</pub-id><?supplied-pmid 20816182?><pub-id pub-id-type="pmid">20816182</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallol</surname><given-names>J.</given-names></name><name><surname>Crane</surname><given-names>J.</given-names></name><name><surname>von Mutius</surname><given-names>E.</given-names></name><name><surname>Odhiambo</surname><given-names>J.</given-names></name><name><surname>Keil</surname><given-names>U.</given-names></name><name><surname>Stewart</surname><given-names>A.</given-names></name></person-group><article-title>The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis</article-title><source>Allergologia et Immunopathologia</source><year>2013</year><volume>41</volume><issue>2</issue><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.aller.2012.03.001</pub-id><pub-id pub-id-type="pmid">22771150</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J.</given-names></name><name><surname>Khaltaev</surname><given-names>N.</given-names></name><name><surname>Cruz</surname><given-names>A. A.</given-names></name><name><surname>Denburg</surname><given-names>J.</given-names></name><name><surname>Fokkens</surname><given-names>W. J.</given-names></name><name><surname>Togias</surname><given-names>A.</given-names></name><name><surname>Zuberbier</surname><given-names>T.</given-names></name><name><surname>Baena-Cagnani</surname><given-names>C. E.</given-names></name><name><surname>Canonica</surname><given-names>G. W.</given-names></name><name><surname>Van Weel</surname><given-names>C.</given-names></name><name><surname>Agache</surname><given-names>I.</given-names></name><name><surname>A&#x000ef;t-Khaled</surname><given-names>N.</given-names></name><name><surname>Bachert</surname><given-names>C.</given-names></name><name><surname>Blaiss</surname><given-names>M. S.</given-names></name><name><surname>Bonini</surname><given-names>S.</given-names></name><name><surname>Boulet</surname><given-names>L.-P.</given-names></name><name><surname>Bousquet</surname><given-names>P.-J.</given-names></name><name><surname>Camargos</surname><given-names>P.</given-names></name><name><surname>Carlsen</surname><given-names>K.-H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Custovic</surname><given-names>A.</given-names></name><name><surname>Dahl</surname><given-names>R.</given-names></name><name><surname>Demoly</surname><given-names>P.</given-names></name><name><surname>Douagui</surname><given-names>H.</given-names></name><name><surname>Durham</surname><given-names>S. R.</given-names></name><name><surname>Van Wijk</surname><given-names>R. Gerth</given-names></name><name><surname>Kalayci</surname><given-names>O.</given-names></name><name><surname>Kaliner</surname><given-names>M. A.</given-names></name><name><surname>Kim</surname><given-names>Y.-Y.</given-names></name><name><surname>Kowalski</surname><given-names>M. L.</given-names></name><name><surname>Kuna</surname><given-names>P.</given-names></name><name><surname>Le</surname><given-names>L. T. T.</given-names></name><name><surname>Lemiere</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lockey</surname><given-names>R. F.</given-names></name><name><surname>Mavale-Manuel</surname><given-names>S.</given-names></name><name><surname>Meltzer</surname><given-names>E. O.</given-names></name><name><surname>Mohammad</surname><given-names>Y.</given-names></name><name><surname>Mullol</surname><given-names>J.</given-names></name><name><surname>Naclerio</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Hehir</surname><given-names>R. E.</given-names></name><name><surname>Ohta</surname><given-names>K.</given-names></name><name><surname>Ouedraogo</surname><given-names>S.</given-names></name><name><surname>Palkonen</surname><given-names>S.</given-names></name><name><surname>Papadopoulos</surname><given-names>N.</given-names></name><name><surname>Passalacqua</surname><given-names>G.</given-names></name><name><surname>Pawankar</surname><given-names>R.</given-names></name><name><surname>Popov</surname><given-names>T. A.</given-names></name><name><surname>Rabe</surname><given-names>K. F.</given-names></name><name><surname>Rosado-Pinto</surname><given-names>J.</given-names></name><name><surname>Scadding</surname><given-names>G. K.</given-names></name><name><surname>Simons</surname><given-names>F. E. R.</given-names></name><name><surname>Toskala</surname><given-names>E.</given-names></name><name><surname>Valovirta</surname><given-names>E.</given-names></name><name><surname>Van Cauwenberge</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>D.-Y.</given-names></name><name><surname>Wickman</surname><given-names>M.</given-names></name><name><surname>Yawn</surname><given-names>B. P.</given-names></name><name><surname>Yorgancioglu</surname><given-names>A.</given-names></name><name><surname>Yusuf</surname><given-names>O. M.</given-names></name><name><surname>Zar</surname><given-names>H.</given-names></name><name><surname>Annesi-Maesano</surname><given-names>I.</given-names></name><name><surname>Bateman</surname><given-names>E. D.</given-names></name><name><surname>Kheder</surname><given-names>A. Ben</given-names></name><name><surname>Boakye</surname><given-names>D. A.</given-names></name><name><surname>Bouchard</surname><given-names>J.</given-names></name><name><surname>Burney</surname><given-names>P.</given-names></name><name><surname>Busse</surname><given-names>W. W.</given-names></name><name><surname>Chan-Yeung</surname><given-names>M.</given-names></name><name><surname>Chavannes</surname><given-names>N. H.</given-names></name><name><surname>Chuchalin</surname><given-names>A.</given-names></name><name><surname>Dolen</surname><given-names>W. K.</given-names></name><name><surname>Emuzyte</surname><given-names>R.</given-names></name><name><surname>Grouse</surname><given-names>L.</given-names></name><name><surname>Humbert</surname><given-names>M.</given-names></name><name><surname>Jackson</surname><given-names>C.</given-names></name><name><surname>Johnston</surname><given-names>S. L.</given-names></name><name><surname>Keith</surname><given-names>P. K.</given-names></name><name><surname>Kemp</surname><given-names>J. P.</given-names></name><name><surname>Klossek</surname><given-names>J.-M.</given-names></name><name><surname>Larenas-Linnemann</surname><given-names>D.</given-names></name><name><surname>Lipworth</surname><given-names>B.</given-names></name><name><surname>Malo</surname><given-names>J.-L.</given-names></name><name><surname>Marshall</surname><given-names>G. D.</given-names></name><name><surname>Naspitz</surname><given-names>C.</given-names></name><name><surname>Nekam</surname><given-names>K.</given-names></name><name><surname>Niggemann</surname><given-names>B.</given-names></name><name><surname>Nizankowska-Mogilnicka</surname><given-names>E.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name><name><surname>Orru</surname><given-names>M. P.</given-names></name><name><surname>Potter</surname><given-names>P.</given-names></name><name><surname>Price</surname><given-names>D.</given-names></name><name><surname>Stoloff</surname><given-names>S. W.</given-names></name><name><surname>Vandenplas</surname><given-names>O.</given-names></name><name><surname>Viegi</surname><given-names>G.</given-names></name><name><surname>Williams</surname><given-names>D.</given-names></name></person-group><article-title>Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>8</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2007.01620.x</pub-id><pub-id pub-id-type="pmid">18331513</pub-id></element-citation></ref><ref id="CR11"><label>11&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Van Cauwenberge</surname><given-names>P</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name><collab>ARIA workshop group; World Health Organization</collab></person-group><article-title>Allergic rhinitis and its impact on asthma</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><fpage>S147</fpage><lpage>S334</lpage><pub-id pub-id-type="doi">10.1067/mai.2001.118891</pub-id><?supplied-pmid 11707753?><pub-id pub-id-type="pmid">11707753</pub-id></element-citation></ref><ref id="CR12"><label>12&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>SK</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name></person-group><article-title>International consensus statement on allergy and rhinology: allergic rhinitis&#x02014;executive summary</article-title><source>Int Forum Allergy Rhinol</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>85</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1002/alr.22070</pub-id><?supplied-pmid 29438600?><pub-id pub-id-type="pmid">29438600</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varney</surname><given-names>VA</given-names></name><name><surname>Jacobson</surname><given-names>MR</given-names></name><name><surname>Sudderick</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>146</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.5415/apallergy.2011.1.3.157</pub-id><?supplied-pmid 1626799?><pub-id pub-id-type="pmid">1626799</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridolo</surname><given-names>E</given-names></name><name><surname>Martignago</surname><given-names>I</given-names></name><name><surname>Masieri</surname><given-names>S</given-names></name></person-group><article-title>Mechanisms of allergic diseases in otorhinolaryngology</article-title><source>J Biol Regul Homeost Agents</source><year>2018</year><volume>32</volume><issue>Suppl. 1</issue><fpage>9</fpage><lpage>12</lpage><?supplied-pmid 29552867?><pub-id pub-id-type="pmid">29552867</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creticos</surname><given-names>PS</given-names></name><name><surname>Peters</surname><given-names>SP</given-names></name><name><surname>Adkinson</surname><given-names>NF</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Peptide leukotriene release after antigen challenge in patients sensitive to ragweed</article-title><source>N Engl J Med</source><year>1984</year><volume>310</volume><fpage>1626</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1056/NEJM198406213102502</pub-id><?supplied-pmid 6328300?><pub-id pub-id-type="pmid">6328300</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BENTLEY</surname><given-names>A</given-names></name><name><surname>JACOBSON</surname><given-names>M</given-names></name><name><surname>CUMBERWORTH</surname><given-names>V</given-names></name><name><surname>BARKANS</surname><given-names>J</given-names></name><name><surname>MOQBEL</surname><given-names>R</given-names></name><name><surname>SCHWARTZ</surname><given-names>L</given-names></name><name><surname>IRANI</surname><given-names>A</given-names></name><name><surname>KAY</surname><given-names>A</given-names></name><name><surname>DURHAM</surname><given-names>S</given-names></name></person-group><article-title>Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells</article-title><source>Journal of Allergy and Clinical Immunology</source><year>1992</year><volume>89</volume><issue>4</issue><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/0091-6749(92)90444-7</pub-id><pub-id pub-id-type="pmid">1532808</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Caruso B, Ferrari A, Melloni N, Rocca M, Nicolis D, Cocco C, et al. Component resolved diagnosis (CRD): in-vitro definition of allergic patient&#x02019;s profile. Rivista Italiana della Medicina di Laboratorio. 2009;5:90&#x02013;5.</mixed-citation></ref><ref id="CR18"><label>18&#x02022;&#x02022;</label><mixed-citation publication-type="other">Campo P, Eguiluz-Gracia I, Bogas G, Salas M, Plaza Ser&#x000f3;n C, P&#x000e9;rez N, et al. Local allergic rhinitis: implications for management. Clin Exp Allergy. 2019;49:6&#x02013;16. 10.1111/cea.13192This paper is a very good review on local allergic rhinitis.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rond&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Romero</surname><given-names>JJ</given-names></name><name><surname>Lopez</surname><given-names>S</given-names></name><etal/></person-group><article-title>Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2007</year><volume>119</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2007.01.006</pub-id><?supplied-pmid 17337294?><pub-id pub-id-type="pmid">17337294</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondo&#x000f3;</surname><given-names>C</given-names></name><name><surname>Dona</surname><given-names>I</given-names></name><name><surname>Lopez</surname><given-names>S</given-names></name><etal/></person-group><article-title>Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>1352</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2008.01695.x</pub-id><pub-id pub-id-type="pmid">18782115</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powe</surname><given-names>DG</given-names></name><name><surname>Huskisson</surname><given-names>RS</given-names></name><name><surname>Carney</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Mucosal T-cell phenotypes in persistent atopic and nonatopic rhinitis show an association with mast cells</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1046/j.1398-9995.2003.00315.x</pub-id><?supplied-pmid 14763935?><pub-id pub-id-type="pmid">14763935</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>Cezmi A.</given-names></name><name><surname>Bachert</surname><given-names>Claus</given-names></name><name><surname>Cingi</surname><given-names>Cemal</given-names></name><name><surname>Dykewicz</surname><given-names>Mark S.</given-names></name><name><surname>Hellings</surname><given-names>Peter W.</given-names></name><name><surname>Naclerio</surname><given-names>Robert M.</given-names></name><name><surname>Schleimer</surname><given-names>Robert P.</given-names></name><name><surname>Ledford</surname><given-names>Dennis</given-names></name></person-group><article-title>Endotypes and phenotypes of chronic rhinosinusitis: A&#x000a0;PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &#x00026; Immunology</article-title><source>Journal of Allergy and Clinical Immunology</source><year>2013</year><volume>131</volume><issue>6</issue><fpage>1479</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.02.036</pub-id><pub-id pub-id-type="pmid">23587334</pub-id></element-citation></ref><ref id="CR23"><label>23&#x02022;&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>NG</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Dykewicz</surname><given-names>M</given-names></name><name><surname>Fokkens</surname><given-names>W</given-names></name><name><surname>Hellings</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report</article-title><source>Allergy</source><year>2015</year><volume>70</volume><fpage>474</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1111/all.12573</pub-id><?supplied-pmid 25620381?><pub-id pub-id-type="pmid">25620381</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleine-Tebbe</surname><given-names>J</given-names></name><name><surname>Matricardi</surname><given-names>PM</given-names></name><name><surname>Hamilton</surname><given-names>RG</given-names></name></person-group><article-title>Allergy work-up including component-resolved diagnosis: how to make allergen-specific immunotherapy more specific</article-title><source>Immunol Allergy Clin N Am</source><year>2016</year><volume>36</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2015.08.012</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>F</given-names></name><name><surname>Tripodi</surname><given-names>S</given-names></name><name><surname>Panetta</surname><given-names>V</given-names></name><etal/></person-group><article-title>Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: a longitudinal multicenter study of a patient cohort</article-title><source>Pediatr Allergy Immunol</source><year>2019</year><volume>30</volume><issue>3</issue><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1111/pai.13036</pub-id><?supplied-pmid 30734368?><pub-id pub-id-type="pmid">30734368</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGlashan</surname><given-names>DW</given-names><suffix>Jr</suffix></name></person-group><article-title>Basophil activation testing</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>132</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.06.038</pub-id><?supplied-pmid 23958648?><pub-id pub-id-type="pmid">23958648</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gasse</surname><given-names>AL</given-names></name><name><surname>Mangodt</surname><given-names>EA</given-names></name><name><surname>Faber</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular allergy diagnosis: status anno 2015</article-title><source>Clin Chim Acta</source><year>2015</year><volume>444</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.02.012</pub-id><?supplied-pmid 25681645?><pub-id pub-id-type="pmid">25681645</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys S. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017. 10.1186/s13601-017-0157-8.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aug&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Vent</surname><given-names>J.</given-names></name><name><surname>Agache</surname><given-names>I.</given-names></name><name><surname>Airaksinen</surname><given-names>L.</given-names></name><name><surname>Campo Mozo</surname><given-names>P.</given-names></name><name><surname>Chaker</surname><given-names>A.</given-names></name><name><surname>Cingi</surname><given-names>C.</given-names></name><name><surname>Durham</surname><given-names>S.</given-names></name><name><surname>Fokkens</surname><given-names>W.</given-names></name><name><surname>Gevaert</surname><given-names>P.</given-names></name><name><surname>Giotakis</surname><given-names>A.</given-names></name><name><surname>Hellings</surname><given-names>P.</given-names></name><name><surname>Herknerova</surname><given-names>M.</given-names></name><name><surname>Hox</surname><given-names>V.</given-names></name><name><surname>Klimek</surname><given-names>L.</given-names></name><name><surname>La Melia</surname><given-names>C.</given-names></name><name><surname>Mullol</surname><given-names>J.</given-names></name><name><surname>Muluk</surname><given-names>N. B.</given-names></name><name><surname>Muraro</surname><given-names>A.</given-names></name><name><surname>Naito</surname><given-names>K.</given-names></name><name><surname>Pfaar</surname><given-names>O.</given-names></name><name><surname>Riechelmann</surname><given-names>H.</given-names></name><name><surname>Rondon</surname><given-names>C.</given-names></name><name><surname>Rudenko</surname><given-names>M.</given-names></name><name><surname>Samolinski</surname><given-names>B.</given-names></name><name><surname>Tasca</surname><given-names>I.</given-names></name><name><surname>Tomazic</surname><given-names>P.</given-names></name><name><surname>Vogt</surname><given-names>K.</given-names></name><name><surname>Wagenmann</surname><given-names>M.</given-names></name><name><surname>Yeryomenko</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>M&#x000f6;sges</surname><given-names>R.</given-names></name></person-group><article-title>EAACI Position paper on the standardization of nasal allergen challenges</article-title><source>Allergy</source><year>2018</year><volume>73</volume><issue>8</issue><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1111/all.13416</pub-id><pub-id pub-id-type="pmid">29377177</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maniscalco</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Vatrella</surname><given-names>A</given-names></name><name><surname>Molino</surname><given-names>A</given-names></name><name><surname>Bianco</surname><given-names>A</given-names></name><name><surname>Mazzarella</surname><given-names>G</given-names></name></person-group><article-title>Fractional exhaled nitric oxide-measuring devices: technology update</article-title><source>Med Devices (Auckl)</source><year>2016</year><volume>9</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.2147/MDER.S91201</pub-id><pub-id pub-id-type="pmid">27382340</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Arnal JF, Didier A, Rami J, M&#x02019;Rini C, Charlet JP, Serrano E, et al. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy. 1997;27:358&#x02013;62.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passioti</surname><given-names>M</given-names></name><name><surname>Maggina</surname><given-names>P</given-names></name><name><surname>Megremis</surname><given-names>S</given-names></name><name><surname>Papadopoulos</surname><given-names>NG</given-names></name></person-group><article-title>The common cold: potential for future prevention or cure</article-title><source>Curr Allergy Asthma Rep</source><year>2014</year><volume>14</volume><fpage>413</fpage><pub-id pub-id-type="doi">10.1007/s11882-013-0413-5</pub-id><?supplied-pmid 24415465?><pub-id pub-id-type="pmid">24415465</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kempen</surname><given-names>M</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Van Cauwenberge</surname><given-names>P</given-names></name></person-group><article-title>An update on the pathophysiology of rhinovirus upper respiratory tract infections</article-title><source>Rhinology</source><year>1999</year><volume>37</volume><fpage>97</fpage><lpage>103</lpage><?supplied-pmid 10567986?><pub-id pub-id-type="pmid">10567986</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>O</given-names></name><name><surname>Carenfelt</surname><given-names>C</given-names></name><name><surname>Rystedt</surname><given-names>G</given-names></name><name><surname>Angg&#x000e5;rd</surname><given-names>A</given-names></name></person-group><article-title>Occurrence of asymptomatic sinusitis in common cold and other acute ENT-infections</article-title><source>Rhinology</source><year>1986</year><volume>24</volume><fpage>223</fpage><lpage>225</lpage><?supplied-pmid 3775189?><pub-id pub-id-type="pmid">3775189</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hekiert</surname><given-names>AM</given-names></name><name><surname>Kofonow</surname><given-names>JM</given-names></name><name><surname>Doghramji</surname><given-names>L</given-names></name><etal/></person-group><article-title>Biofilms correlate with TH1 inflammation in the sinonasal tissue of patients with chronic rhinosinusitis</article-title><source>Otolaryngol Head Neck Surg</source><year>2009</year><volume>141</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.otohns.2009.06.090</pub-id><?supplied-pmid 19786211?><pub-id pub-id-type="pmid">19786211</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bruaene</surname><given-names>N</given-names></name><name><surname>Derycke</surname><given-names>L</given-names></name><name><surname>Perez-Novo</surname><given-names>CA</given-names></name><etal/></person-group><article-title>TGF-beta signaling and collagen deposition in chronic rhinosinusitis</article-title><source>J Allergy Clin Immunol</source><year>2009</year><volume>124</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.04.013</pub-id><?supplied-pmid 19500825?><pub-id pub-id-type="pmid">19500825</pub-id></element-citation></ref><ref id="CR37"><label>37&#x02022;&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>NG</given-names></name><name><surname>Guibas</surname><given-names>GV</given-names></name></person-group><article-title>Rhinitis subtypes, endotypes, and definitions</article-title><source>Immunol Allergy Clin North Am</source><year>2016</year><volume>36</volume><issue>2</issue><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2015.12.001</pub-id><?supplied-pmid 27083098?><pub-id pub-id-type="pmid">27083098</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Zele</surname><given-names>T</given-names></name><name><surname>Gevaert</surname><given-names>P</given-names></name><name><surname>Watelet</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>114</volume><fpage>981</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2004.07.013</pub-id><pub-id pub-id-type="pmid">15480349</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Role of exhaled nasal nitric oxide in distinguishing between chronic rhinosinusitis with and without nasal polyps</article-title><source>Am J Rhinol Allergy</source><year>2017</year><volume>31</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.2500/ajra.2017.31.4480</pub-id><?supplied-pmid 28927489?><pub-id pub-id-type="pmid">28927489</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Settipane</surname><given-names>RA</given-names></name><name><surname>Charnock</surname><given-names>DR</given-names></name></person-group><article-title>Epidemiology of rhinitis: allergic and nonallergic</article-title><source>Clin Allergy Immunol</source><year>2007</year><volume>19</volume><fpage>23</fpage><lpage>34</lpage><?supplied-pmid 17153005?><pub-id pub-id-type="pmid">17153005</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>AK</given-names></name><name><surname>Keith</surname><given-names>PK</given-names></name></person-group><article-title>Nonallergic rhinitis with eosinophilia syndrome and related disorders</article-title><source>Clin Allergy Immunol.</source><year>2007</year><volume>19</volume><fpage>87</fpage><lpage>100</lpage><?supplied-pmid 17153009?><pub-id pub-id-type="pmid">17153009</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Van Bruaene</surname><given-names>N</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name><etal/></person-group><article-title>Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis&#x02014;a GALEN study</article-title><source>Allergy</source><year>2009</year><volume>64</volume><fpage>520</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2009.01964.x</pub-id><?supplied-pmid 19317839?><pub-id pub-id-type="pmid">19317839</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moneret-Vautrin</surname><given-names>DA</given-names></name><name><surname>Hsieh</surname><given-names>V</given-names></name><name><surname>Wayoff</surname><given-names>M</given-names></name><name><surname>Guyot</surname><given-names>JL</given-names></name><name><surname>Mouton</surname><given-names>C</given-names></name><name><surname>Maria</surname><given-names>Y</given-names></name></person-group><article-title>Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin</article-title><source>Ann Allergy</source><year>1990</year><volume>64</volume><fpage>513</fpage><lpage>518</lpage><?supplied-pmid 2346237?><pub-id pub-id-type="pmid">2346237</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>AK</given-names></name><name><surname>Keith</surname><given-names>PK</given-names></name></person-group><article-title>Nonallergic rhinitis with eosinophilia syndrome</article-title><source>Curr Allergy Asthma Rep</source><year>2006</year><volume>6</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s11882-006-0037-0</pub-id><pub-id pub-id-type="pmid">16579871</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>Sven</given-names></name><name><surname>Rasp</surname><given-names>Julia</given-names></name><name><surname>Eder</surname><given-names>Katharina</given-names></name><name><surname>Berghaus</surname><given-names>Alexander</given-names></name><name><surname>Kramer</surname><given-names>Matthias F.</given-names></name><name><surname>Gr&#x000f6;ger</surname><given-names>Moritz</given-names></name></person-group><article-title>Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa</article-title><source>European Archives of Oto-Rhino-Laryngology</source><year>2015</year><volume>273</volume><issue>6</issue><fpage>1469</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1007/s00405-015-3769-4</pub-id><pub-id pub-id-type="pmid">26342925</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Settipane</surname><given-names>G</given-names></name></person-group><article-title>Epidemiology of vasomotor rhinitis</article-title><source>World Allergy Organ J</source><year>2009</year><volume>2</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1097/WOX.0b013e3181ac91ae</pub-id><pub-id pub-id-type="pmid">24229078</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaradeh</surname><given-names>Safwan S.</given-names></name><name><surname>Smith</surname><given-names>Timothy L.</given-names></name><name><surname>Torrico</surname><given-names>Laura</given-names></name><name><surname>Prieto</surname><given-names>Thomas E.</given-names></name><name><surname>Loehrl</surname><given-names>Todd A.</given-names></name><name><surname>Darling</surname><given-names>Ronald J.</given-names></name><name><surname>Toohill</surname><given-names>Robert J.</given-names></name></person-group><article-title>Autonomic Nervous System Evaluation of Patients With Vasomotor Rhinitis</article-title><source>The Laryngoscope</source><year>2000</year><volume>110</volume><issue>11</issue><fpage>1828</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1097/00005537-200011000-00012</pub-id><pub-id pub-id-type="pmid">11081594</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gerven</surname><given-names>L</given-names></name><name><surname>Boeckxstaens</surname><given-names>G</given-names></name><name><surname>Hellings</surname><given-names>P</given-names></name></person-group><article-title>Up-date on neuro-immune mechanisms involved in allergic and non-allergic rhinitis</article-title><source>Rhinology</source><year>2012</year><volume>50</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.4193/Rhin11.152</pub-id><?supplied-pmid 22888478?><pub-id pub-id-type="pmid">22888478</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarin</surname><given-names>S</given-names></name><name><surname>Undem</surname><given-names>B</given-names></name><name><surname>Sanico</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of the nervous system in rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>118</volume><fpage>999</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.09.013</pub-id><pub-id pub-id-type="pmid">17088122</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin-Yilmaz</surname><given-names>AA</given-names></name><name><surname>Corey</surname><given-names>JP</given-names></name></person-group><article-title>Rhinitis in the elderly</article-title><source>Clin Allergy Immunol</source><year>2007</year><volume>19</volume><fpage>209</fpage><lpage>219</lpage><?supplied-pmid 17153015?><pub-id pub-id-type="pmid">17153015</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgalas</surname><given-names>C</given-names></name><name><surname>Jovancevic</surname><given-names>L</given-names></name></person-group><article-title>Gustatory rhinitis</article-title><source>Curr Opin Otolaryngol Head Neck Surg</source><year>2012</year><volume>20</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.4193/Rhin07.153</pub-id><?supplied-pmid 22143339?><pub-id pub-id-type="pmid">22143339</pub-id></element-citation></ref><ref id="CR52"><label>52&#x02022;&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraro</surname><given-names>A</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names><suffix>Jr</suffix></name><name><surname>Hellings</surname><given-names>PW</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Casale</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis&#x02014;PRACTALL document of the European academy of allergy and clinical immunology and the American Academy of Allergy, Asthma &#x00026; Immunology</article-title><source>J Allergy Clin Immunol</source><year>2016</year><volume>137</volume><fpage>1347</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.03.010</pub-id><?supplied-pmid 27155030?><pub-id pub-id-type="pmid">27155030</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gerven</surname><given-names>L</given-names></name><name><surname>Alpizar</surname><given-names>YA</given-names></name><name><surname>Wouters</surname><given-names>MM</given-names></name><name><surname>Hox</surname><given-names>V</given-names></name><name><surname>Hauben</surname><given-names>E</given-names></name><name><surname>Jorissen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2014</year><volume>133</volume><fpage>1332</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.08.026</pub-id><?supplied-pmid 24139494?><pub-id pub-id-type="pmid">24139494</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Orban N, Maughan E, Bleach N. Pregnancy-induced rhinitis. Rhinology. 2013Jun;51(2):111&#x02013;9. 10.4193/Rhino12.045.</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamano</surname><given-names>N</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name><name><surname>Maesako</surname><given-names>K</given-names></name><etal/></person-group><article-title>Expression of histamine receptors in nasal epithelial cells and endothelial cells&#x02014;the effects of sex hormones</article-title><source>Int Arch Allergy Immunol</source><year>2008</year><volume>115</volume><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1159/000023904</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>JL</given-names></name><name><surname>Stoner</surname><given-names>AN</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future</article-title><source>Am J Rhinol Allergy</source><year>2016</year><volume>30</volume><issue>6</issue><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.2500/ajra.2016.30.4370</pub-id><?supplied-pmid 28124651?><pub-id pub-id-type="pmid">28124651</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>M</given-names></name><name><surname>Glaum</surname><given-names>MC</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name></person-group><article-title>Drug-induced rhinitis</article-title><source>Clin Exp Allergy</source><year>2010</year><volume>40</volume><fpage>381</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2009.03450.x</pub-id><?supplied-pmid 20210811?><pub-id pub-id-type="pmid">20210811</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramey</surname><given-names>JT</given-names></name><name><surname>Bailen</surname><given-names>E</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name></person-group><article-title>Rhinitis Medicamentosa</article-title><source>J Investig Allergol Clin Immunol</source><year>2006</year><volume>16</volume><issue>3</issue><fpage>148</fpage><lpage>155</lpage><?supplied-pmid 16784007?><pub-id pub-id-type="pmid">16784007</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>WW</given-names></name><name><surname>Grammer</surname><given-names>LC</given-names></name></person-group><article-title>Occupational rhinitis: an update</article-title><source>Curr Allergy Asthma Rep</source><year>2015</year><volume>15</volume><issue>1</issue><fpage>487</fpage><pub-id pub-id-type="doi">10.1007/s11882-014-0487-8</pub-id><?supplied-pmid 25430949?><pub-id pub-id-type="pmid">25430949</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroyer</surname><given-names>C.</given-names></name><name><surname>Malo</surname><given-names>J. L.</given-names></name><name><surname>Girard</surname><given-names>D.</given-names></name><name><surname>Dufour</surname><given-names>J. G.</given-names></name><name><surname>Gautrin</surname><given-names>D.</given-names></name></person-group><article-title>Chronic rhinitis in workers at risk of reactive airways dysfunction syndrome due to exposure to chlorine</article-title><source>Occupational and Environmental Medicine</source><year>1999</year><volume>56</volume><issue>5</issue><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1136/oem.56.5.334</pub-id><pub-id pub-id-type="pmid">10472308</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siracusa</surname><given-names>Andrea</given-names></name><name><surname>Folletti</surname><given-names>Ilenia</given-names></name><name><surname>Moscato</surname><given-names>Gianna</given-names></name></person-group><article-title>Non-IgE-mediated and irritant-induced work-related rhinitis</article-title><source>Current Opinion in Allergy and Clinical Immunology</source><year>2013</year><volume>13</volume><issue>2</issue><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1097/ACI.0b013e32835e12e7</pub-id><pub-id pub-id-type="pmid">23324747</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dykewicz</surname><given-names>MS</given-names></name></person-group><article-title>Management of rhinitis: guidelines, evidence basis, and systematic clinical approach for what we do</article-title><source>Immunol Allergy Clin N Am</source><year>2011</year><volume>31</volume><fpage>619</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2011.05.002</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>Jean</given-names></name><name><surname>Pfaar</surname><given-names>Oliver</given-names></name><name><surname>Togias</surname><given-names>Alkis</given-names></name><name><surname>Sch&#x000fc;nemann</surname><given-names>Holger J.</given-names></name><name><surname>Ansotegui</surname><given-names>Ignacio</given-names></name><name><surname>Papadopoulos</surname><given-names>Nikolaos G.</given-names></name><name><surname>Tsiligianni</surname><given-names>Ioanna</given-names></name><name><surname>Agache</surname><given-names>Ioana</given-names></name><name><surname>Anto</surname><given-names>Josep M.</given-names></name><name><surname>Bachert</surname><given-names>Claus</given-names></name><name><surname>Bedbrook</surname><given-names>Anna</given-names></name><name><surname>Bergmann</surname><given-names>Karl&#x02010;Christian</given-names></name><name><surname>Bosnic&#x02010;Anticevich</surname><given-names>Sinthia</given-names></name><name><surname>Bosse</surname><given-names>Isabelle</given-names></name><name><surname>Brozek</surname><given-names>Jan</given-names></name><name><surname>Calderon</surname><given-names>Moises A.</given-names></name><name><surname>Canonica</surname><given-names>Giorgio W.</given-names></name><name><surname>Caraballo</surname><given-names>Luigi</given-names></name><name><surname>Cardona</surname><given-names>Victoria</given-names></name><name><surname>Casale</surname><given-names>Thomas</given-names></name><name><surname>Cecchi</surname><given-names>Lorenzo</given-names></name><name><surname>Chu</surname><given-names>Derek</given-names></name><name><surname>Costa</surname><given-names>Elisio</given-names></name><name><surname>Cruz</surname><given-names>Alvaro A.</given-names></name><name><surname>Czarlewski</surname><given-names>Wienczyslawa</given-names></name><name><surname>Durham</surname><given-names>Stephen R.</given-names></name><name><surname>Du Toit</surname><given-names>George</given-names></name><name><surname>Dykewicz</surname><given-names>Mark</given-names></name><name><surname>Ebisawa</surname><given-names>Motohiro</given-names></name><name><surname>Fauquert</surname><given-names>Jean Luc</given-names></name><name><surname>Fernandez&#x02010;Rivas</surname><given-names>Montserrat</given-names></name><name><surname>Fokkens</surname><given-names>Wytske J.</given-names></name><name><surname>Fonseca</surname><given-names>Jo&#x000e3;o</given-names></name><name><surname>Fontaine</surname><given-names>Jean&#x02010;Fran&#x000e7;ois</given-names></name><name><surname>Gerth van Wijk</surname><given-names>Roy</given-names></name><name><surname>Haahtela</surname><given-names>Tari</given-names></name><name><surname>Halken</surname><given-names>Susanne</given-names></name><name><surname>Hellings</surname><given-names>Peter W.</given-names></name><name><surname>Ierodiakonou</surname><given-names>Despo</given-names></name><name><surname>Iinuma</surname><given-names>Tomohisa</given-names></name><name><surname>Ivancevich</surname><given-names>Juan Carlos</given-names></name><name><surname>Jacobsen</surname><given-names>Lars</given-names></name><name><surname>Jutel</surname><given-names>Marek</given-names></name><name><surname>Kaidashev</surname><given-names>Igor</given-names></name><name><surname>Khaitov</surname><given-names>Musa</given-names></name><name><surname>Kalayci</surname><given-names>Omer</given-names></name><name><surname>Kleine Tebbe</surname><given-names>J&#x000f6;rg</given-names></name><name><surname>Klimek</surname><given-names>Ludger</given-names></name><name><surname>Kowalski</surname><given-names>Marek L.</given-names></name><name><surname>Kuna</surname><given-names>Piotr</given-names></name><name><surname>Kvedariene</surname><given-names>Violeta</given-names></name><name><surname>La Grutta</surname><given-names>Stefania</given-names></name><name><surname>Larenas&#x02010;Linemann</surname><given-names>D&#x000e9;sir&#x000e9;e</given-names></name><name><surname>Lau</surname><given-names>Susanne</given-names></name><name><surname>Laune</surname><given-names>Daniel</given-names></name><name><surname>Le</surname><given-names>Lan</given-names></name><name><surname>Lodrup Carlsen</surname><given-names>Karin</given-names></name><name><surname>Louren&#x000e7;o</surname><given-names>Olga</given-names></name><name><surname>Malling</surname><given-names>Hans&#x02010;J&#x000f8;rgen</given-names></name><name><surname>Marien</surname><given-names>Gert</given-names></name><name><surname>Menditto</surname><given-names>Enrica</given-names></name><name><surname>Mercier</surname><given-names>Gregoire</given-names></name><name><surname>Mullol</surname><given-names>Joaquim</given-names></name><name><surname>Muraro</surname><given-names>Antonella</given-names></name><name><surname>O&#x02019;Hehir</surname><given-names>Robyn</given-names></name><name><surname>Okamoto</surname><given-names>Yoshitaka</given-names></name><name><surname>Pajno</surname><given-names>Giovanni B.</given-names></name><name><surname>Park</surname><given-names>Hae&#x02010;Sim</given-names></name><name><surname>Panzner</surname><given-names>Petr</given-names></name><name><surname>Passalacqua</surname><given-names>Giovanni</given-names></name><name><surname>Pham&#x02010;Thi</surname><given-names>Nhan</given-names></name><name><surname>Roberts</surname><given-names>Graham</given-names></name><name><surname>Pawankar</surname><given-names>Ruby</given-names></name><name><surname>Rolland</surname><given-names>Christine</given-names></name><name><surname>Rosario</surname><given-names>Nelson</given-names></name><name><surname>Ryan</surname><given-names>Dermot</given-names></name><name><surname>Samolinski</surname><given-names>Boles&#x00142;aw</given-names></name><name><surname>Sanchez&#x02010;Borges</surname><given-names>Mario</given-names></name><name><surname>Scadding</surname><given-names>Glenis</given-names></name><name><surname>Shamji</surname><given-names>Mohamed H.</given-names></name><name><surname>Sheikh</surname><given-names>Aziz</given-names></name><name><surname>Sturm</surname><given-names>Gunter J.</given-names></name><name><surname>Todo Bom</surname><given-names>Ana</given-names></name><name><surname>Toppila&#x02010;Salmi</surname><given-names>Sanna</given-names></name><name><surname>Valentin&#x02010;Rostan</surname><given-names>Maryline</given-names></name><name><surname>Valiulis</surname><given-names>Arunas</given-names></name><name><surname>Valovirta</surname><given-names>Erkka</given-names></name><name><surname>Ventura</surname><given-names>Maria&#x02010;Teresa</given-names></name><name><surname>Wahn</surname><given-names>Ulrich</given-names></name><name><surname>Walker</surname><given-names>Samantha</given-names></name><name><surname>Wallace</surname><given-names>Dana</given-names></name><name><surname>Waserman</surname><given-names>Susan</given-names></name><name><surname>Yorgancioglu</surname><given-names>Arzu</given-names></name><name><surname>Zuberbier</surname><given-names>Torsten</given-names></name></person-group><article-title>2019 ARIA Care pathways for allergen immunotherapy</article-title><source>Allergy</source><year>2019</year><volume>74</volume><issue>11</issue><fpage>2087</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1111/all.13805</pub-id><pub-id pub-id-type="pmid">30955224</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luengo</surname><given-names>O</given-names></name><name><surname>Cardona</surname><given-names>V</given-names></name></person-group><article-title>Component resolved diagnosis: when should it be used?</article-title><source>Clinical and Translational Allergy</source><year>2014</year><volume>4</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/2045-7022-4-28</pub-id><?supplied-pmid 25250172?><pub-id pub-id-type="pmid">25250172</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Barber D, Moreno C, Ledesma A, Serrano P, Gal&#x000e1;n A, Villalba M, et al. Degree of olive pollen exposure and sensitization patterns. Clinical implications. J Investig Allergol Clin Immunol. 2007;17(Suppl 1):11&#x02013;6.</mixed-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douladiris</surname><given-names>N</given-names></name><name><surname>Savvatianos</surname><given-names>S</given-names></name><name><surname>Roumpedaki</surname><given-names>I</given-names></name><name><surname>Skevaki</surname><given-names>C</given-names></name><name><surname>Mitsias</surname><given-names>D</given-names></name><name><surname>Papadopoulos</surname><given-names>NG</given-names></name></person-group><article-title>A molecular diagnostic algorithm to guide pollen immunotherapy in southern Europe: towards component-resolved management of allergic diseases</article-title><source>Int Arch Allergy Immunol</source><year>2013</year><volume>162</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1159/000353113</pub-id><?supplied-pmid 23921568?><pub-id pub-id-type="pmid">23921568</pub-id></element-citation></ref><ref id="CR67"><label>67&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsabouri</surname><given-names>S</given-names></name><name><surname>Tseretopoulou</surname><given-names>X</given-names></name><name><surname>Priftis</surname><given-names>K</given-names></name><name><surname>Ntzani</surname><given-names>EE</given-names></name></person-group><article-title>Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials</article-title><source>J Allergy Clin Immunol Pract</source><year>2014</year><volume>2</volume><issue>3</issue><fpage>332</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2014.02.001</pub-id><?supplied-pmid 24811026?><pub-id pub-id-type="pmid">24811026</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>Sarah K.</given-names></name><name><surname>Lin</surname><given-names>Sandra Y.</given-names></name><name><surname>Toskala</surname><given-names>Elina</given-names></name></person-group><article-title>International consensus statement on allergy and rhinology: allergic rhinitis&#x02014;executive summary</article-title><source>International Forum of Allergy &#x00026; Rhinology</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>85</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1002/alr.22070</pub-id><pub-id pub-id-type="pmid">29438600</pub-id></element-citation></ref><ref id="CR69"><label>69&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsetsos</surname><given-names>N</given-names></name><name><surname>Goudakos</surname><given-names>JK</given-names></name><name><surname>Daskalakis</surname><given-names>D</given-names></name><name><surname>Konstantinidis</surname><given-names>I</given-names></name><name><surname>Markou</surname><given-names>K</given-names></name></person-group><article-title>Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review</article-title><source>Rhinology</source><year>2018</year><volume>56</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.4193/Rhin17.156</pub-id><?supplied-pmid 29396960?><pub-id pub-id-type="pmid">29396960</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivero</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name></person-group><article-title>Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis</article-title><source>Ann Otol Rhinol Laryngol</source><year>2017</year><volume>126</volume><issue>11</issue><fpage>739</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1177/0003489417731782</pub-id><?supplied-pmid 28918644?><pub-id pub-id-type="pmid">28918644</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachert</surname><given-names>Claus</given-names></name><name><surname>Han</surname><given-names>Joseph K</given-names></name><name><surname>Desrosiers</surname><given-names>Martin</given-names></name><name><surname>Hellings</surname><given-names>Peter W</given-names></name><name><surname>Amin</surname><given-names>Nikhil</given-names></name><name><surname>Lee</surname><given-names>Stella E</given-names></name><name><surname>Mullol</surname><given-names>Joaquim</given-names></name><name><surname>Greos</surname><given-names>Leon S</given-names></name><name><surname>Bosso</surname><given-names>John V</given-names></name><name><surname>Laidlaw</surname><given-names>Tanya M</given-names></name><name><surname>Cervin</surname><given-names>Anders U</given-names></name><name><surname>Maspero</surname><given-names>Jorge F</given-names></name><name><surname>Hopkins</surname><given-names>Claire</given-names></name><name><surname>Olze</surname><given-names>Heidi</given-names></name><name><surname>Canonica</surname><given-names>G Walter</given-names></name><name><surname>Paggiaro</surname><given-names>Pierluigi</given-names></name><name><surname>Cho</surname><given-names>Seong H</given-names></name><name><surname>Fokkens</surname><given-names>Wytske J</given-names></name><name><surname>Fujieda</surname><given-names>Shigeharu</given-names></name><name><surname>Zhang</surname><given-names>Mei</given-names></name><name><surname>Lu</surname><given-names>Xin</given-names></name><name><surname>Fan</surname><given-names>Chunpeng</given-names></name><name><surname>Draikiwicz</surname><given-names>Steven</given-names></name><name><surname>Kamat</surname><given-names>Siddhesh A</given-names></name><name><surname>Khan</surname><given-names>Asif</given-names></name><name><surname>Pirozzi</surname><given-names>Gianluca</given-names></name><name><surname>Patel</surname><given-names>Naimish</given-names></name><name><surname>Graham</surname><given-names>Neil M H</given-names></name><name><surname>Ruddy</surname><given-names>Marcella</given-names></name><name><surname>Staudinger</surname><given-names>Heribert</given-names></name><name><surname>Weinreich</surname><given-names>David</given-names></name><name><surname>Stahl</surname><given-names>Neil</given-names></name><name><surname>Yancopoulos</surname><given-names>George D</given-names></name><name><surname>Mannent</surname><given-names>Leda P</given-names></name></person-group><article-title>Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials</article-title><source>The Lancet</source><year>2019</year><volume>394</volume><issue>10209</issue><fpage>1638</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31881-1</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadersohi</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name></person-group><article-title>Contemporary pharmacotherapy for allergic rhinitis and chronic rhinosinusitis</article-title><source>Otolaryngol Clin N Am</source><year>2017</year><volume>50</volume><issue>6</issue><fpage>1135</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1016/j.otc.2017.08.009</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>GM</given-names></name><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name></person-group><article-title>The role of macrolides in chronic rhinosinusitis (CRSsNP and CRSwNP)</article-title><source>Curr Allergy Asthma Rep</source><year>2017</year><volume>17</volume><issue>5</issue><fpage>30</fpage><pub-id pub-id-type="doi">10.1007/s11882-017-0696-z</pub-id><?supplied-pmid 28429305?><pub-id pub-id-type="pmid">28429305</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardusso</surname><given-names>LRF</given-names></name><name><surname>Fen&#x000e1;ndez Caldas</surname><given-names>E</given-names></name></person-group><article-title>The association between ambient air pollution and allergic rhinitis inception and control</article-title><source>Curr Treat Options Allergy</source><year>2018</year><volume>5</volume><issue>2</issue><fpage>221</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s40521-018-0162-8</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">IPCC AR4 WG1. Climate change 2007: the physical science basis. Contribution of Working Group I to the Fourth Assessment Report of the Intergovernmental Panel on Climate Change. Solomon S, Qin D, Manning M, et al., editors. Cambridge University Press; 2007. <ext-link ext-link-type="uri" xlink:href="https://www.ipcc.ch/report/ar4/wg1/">https://www.ipcc.ch/report/ar4/wg1/</ext-link>. Accessed May 12, 2019.</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amato</surname><given-names>Gennaro</given-names></name><name><surname>Pawankar</surname><given-names>Ruby</given-names></name><name><surname>Vitale</surname><given-names>Carolina</given-names></name><name><surname>Lanza</surname><given-names>Maurizia</given-names></name><name><surname>Molino</surname><given-names>Antonio</given-names></name><name><surname>Stanziola</surname><given-names>Anna</given-names></name><name><surname>Sanduzzi</surname><given-names>Alessandro</given-names></name><name><surname>Vatrella</surname><given-names>Alessandro</given-names></name><name><surname>D'Amato</surname><given-names>Maria</given-names></name></person-group><article-title>Climate Change and Air Pollution: Effects on Respiratory Allergy</article-title><source>Allergy, Asthma &#x00026; Immunology Research</source><year>2016</year><volume>8</volume><issue>5</issue><fpage>391</fpage><pub-id pub-id-type="doi">10.4168/aair.2016.8.5.391</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggen</surname><given-names>B</given-names></name></person-group><article-title>The effect of climate change on our health</article-title><source>J Fam Health</source><year>2016</year><volume>26</volume><issue>3</issue><fpage>37</fpage><lpage>38</lpage><?supplied-pmid 27498523?><pub-id pub-id-type="pmid">27498523</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurmatov</surname><given-names>U</given-names></name><name><surname>van Schayck</surname><given-names>CP</given-names></name><name><surname>Hurwitz</surname><given-names>B</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name></person-group><article-title>House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review</article-title><source>Allergy.</source><year>2012</year><volume>67</volume><issue>2</issue><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2011.02752.x</pub-id><?supplied-pmid 22103686?><pub-id pub-id-type="pmid">22103686</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Ardusso LRF, Neffen HE, Fern&#x000e1;ndez-Caldas E, Saranz RJ, Parisi CAS, Tolcachier A, et al. Intervenci&#x000f3;n ambiental en las enfermedades respiratorias. MEDICINA (Buenos Aires). 2019;79:123&#x02013;36.</mixed-citation></ref><ref id="CR80"><label>80&#x02022;</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellings</surname><given-names>PW</given-names></name><name><surname>Klimek</surname><given-names>L</given-names></name><name><surname>Cingi</surname><given-names>C</given-names></name><name><surname>Agache</surname><given-names>I</given-names></name><name><surname>Akdis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Non-allergic rhinitis: position paper of the European academy of allergy and clinical immunology</article-title><source>Allergy</source><year>2017</year><volume>72</volume><issue>11</issue><fpage>1657</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1111/all.13200</pub-id><?supplied-pmid 28474799?><pub-id pub-id-type="pmid">28474799</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimek</surname><given-names>L</given-names></name><name><surname>Dollner</surname><given-names>R</given-names></name><name><surname>Pfaar</surname><given-names>O</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name></person-group><article-title>Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?</article-title><source>Curr Allergy Asthma Rep</source><year>2014</year><volume>14</volume><fpage>441</fpage><pub-id pub-id-type="doi">10.1007/s11882-014-0441-9</pub-id><?supplied-pmid 24682773?><pub-id pub-id-type="pmid">24682773</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmberg</surname><given-names>H</given-names></name><name><surname>Grahne</surname><given-names>B</given-names></name><name><surname>Holopainen</surname><given-names>E</given-names></name><name><surname>Binder</surname><given-names>E</given-names></name></person-group><article-title>Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients</article-title><source>Clin Otolaryngol Allied Sci</source><year>1983</year><volume>8</volume><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2273.1983.tb01441.x</pub-id><pub-id pub-id-type="pmid">6228347</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gerven</surname><given-names>L</given-names></name><name><surname>Steelant</surname><given-names>B</given-names></name><name><surname>Hellings</surname><given-names>PW</given-names></name></person-group><article-title>Nasal hyperreactivity in rhinitis: a diagnostic and therapeutic challenge</article-title><source>Allergy.</source><year>2018</year><volume>73</volume><issue>9</issue><fpage>1784</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1111/all.13453</pub-id><?supplied-pmid 29624710?><pub-id pub-id-type="pmid">29624710</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">Crisci CD, Ardusso LRF, M&#x000e1;spero JF, De Genaro M, Marcipar AM et al. Iniciativa de Medicina de Precisi&#x000f3;n en Enfermedades Respiratorias y Al&#x000e9;rgicas (IMPERA). <ext-link ext-link-type="uri" xlink:href="http://www.iniciativa-impera.org/index.php/fundamentos/mision">http://www.iniciativa-impera.org/index.php/fundamentos/mision</ext-link>. Accessed May 12, 2019.</mixed-citation></ref></ref-list></ref-list></back></article>